Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Authors

Paul G Richardson
Thierry Facon
William I Bensinger, Myeloma & Transplant Program, Swedish Cancer Institute, Seattle, WAFollow
Xavier Leleu
Frank Campana
Sandrine Macé
Marielle Chiron
Helgi van de Velde
Joseph Mikhael

Document Type

Article

Publication Date

3-12-2021

Publication Title

Blood Cancer J

Keywords

washington; seattle; swedish cancer

Clinical Institute

Cancer

Department

Hematology

Department

Oncology

Recommended Citation

Richardson, Paul G; Facon, Thierry; Bensinger, William I; Leleu, Xavier; Campana, Frank; Macé, Sandrine; Chiron, Marielle; van de Velde, Helgi; and Mikhael, Joseph, "Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma." (2021). Articles, Abstracts, and Reports. 4554.
https://digitalcommons.providence.org/publications/4554